½ÃÀ庸°í¼­
»óǰÄÚµå
1494344

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¿¹Ãø(-2028³â) : Áö¿ªº° ºÐ¼® - Àç·áº°, Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°

Asia Pacific Flowable Hemostats Market Forecast to 2028 - Regional Analysis - by Material, Product, Application, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 138 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº 2022³â 1¾ï 7,664¸¸ ´Þ·¯¿¡¼­ 2028³â 2¾ï 7,519¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2028³â±îÁö ¿¬Æò±Õ 7.7%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º´¿ø ¹× ¼ö¼ú ¼¾ÅÍÀÇ Áõ°¡·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå Ȱ¼ºÈ­

ºÎ»óÀº ¿©ÀüÈ÷ °øÁß º¸°Ç¿¡ ÀÖ¾î ½É°¢ÇÑ ¹®Á¦ÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¿Ü»ó ¹× »ç°í »ç·ÊÀÇ Áõ°¡´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¸Å³â ¾à 130¸¸ ¸íÀÌ ±³Åë»ç°í·Î ¸ñ¼ûÀ» ÀÒ°í, 2,000¸¸ ¸í¿¡¼­ 5,000¸¸ ¸íÀÌ Ä¡¸íÀûÀÌÁö ¾ÊÀº ºÎ»óÀ» ÀÔÀ¸¸ç, ±× Áß »ó´ç¼ö°¡ ºÎ»óÀ¸·Î ÀÎÇØ Àå¾Ö¸¦ ÀÔ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ÃâÇ÷ ¶Ç´Â °ú´ÙÃâÇ÷Àº º´¿ø Àü »ç¸ÁÀÇ 3ºÐÀÇ 1 ÀÌ»ó, ù 24½Ã°£ ³» »ç¸ÁÀÇ 40% ÀÌ»óÀ» Â÷ÁöÇÕ´Ï´Ù. ½ºÆ÷Ã÷, »ê¾÷ ÀçÇØ, ³ëÈ­·Î ÀÎÇÑ ±â´É Àå¾Ö¿Í °ü·ÃµÈ ±Ù°ñ°Ý°è ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ¼ö¼ú °Ç¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ºÆ÷Ã÷ °ü·Ã ºÎ»óÀ¸·Î ÀÎÇØ °Ç°­ ÁõÁø¿¡ ´ëÇÑ »ó´ç ºÎºÐÀÌ ¼Õ½ÇµÇ°í ÀÖ½À´Ï´Ù. ±¹¸³ÀÇÇеµ¼­°ü º¸°í¼­¿¡ µû¸£¸é Áß±¹Àº ´Ù¸¥ ³ª¶ó¿¡ ºñÇØ ¿Ü»ó¼º ³ú¼Õ»ó(TBI) ȯÀÚ ¼ö°¡ ¸¹¾Æ °øÁߺ¸°Ç¿¡ Å« ¹®Á¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÎ»ó°ú ¼ö¼úÀÇ Áõ°¡´Â À¯µ¿¼º ÁöÇ÷Á¦ÀÇ ³ôÀº äÅ÷üÀÇ ¿øÀÎÀÌ µÇ¾î ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå °³¿ä

¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, Çѱ¹, È£ÁÖ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ´Ù¸¥ ¸ðµç Áö¿ª Áß °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ¼ºÀåÀº ÇコÄÉ¾î ºÎ¹®ÀÇ ÀÎÇÁ¶ó °³¹ß¿¡ ´ëÇÑ ÅõÀÚ, ¼ö¼ú °Ç¼ö Áõ°¡, ¿ì¼öÇÑ ¼ö¼ú °á°ú Á¦°ø¿¡ ´ëÇÑ Á߿伺 Áõ°¡, À¯¸®ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ µîÀ¸·Î ÀÎÇØ ´õ ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ Áß±¹Àº Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¿ì¼öÇÑ ¿Ü°úÀû Ä¡·áÀÇ Á߿伺ÀÌ °­Á¶µÇ°í ÃֽŠÀÇ·á±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áß±¹ Ç÷¿ìº´ Ä¡·á¼¾ÅÍ Çù·Â ³×Æ®¿öÅ©(Hemophilia Treatment Center Collaboration Network of China, HTCCNC)ÀÇ Á¶»ç¿¡ µû¸£¸é, 2007³âºÎÅÍ 2019³â±îÁö 17,779¸íÀÇ Ç÷¿ìº´ ȯÀÚ¿¡ ´ëÇÑ ÁöÇ÷Á¦ ¼³°è, °³¹ß ¹× ÀÓ»ó½ÃÇèÀÌ ÀÌ·ç¾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 17,779¸íÀÇ Ç÷¿ìº´ A ȯÀÚ¸¦ È®ÀÎÇß½À´Ï´Ù. ȯÀÚ´Â ´ëºÎºÐ ³²¼º(99.99%)À̾ú°í, 28.3%´Â Ç÷¿ìº´ °¡Á··ÂÀÌ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. °Ë»ç·Î ÁßÁõµµ¸¦ ÃøÁ¤ÇÑ È¯ÀÚ(N=13,116¸í) Áß 6,519¸í(49.7%)ÀÌ ÁßÁõ HA, 4,788¸í(36.5%)ÀÌ Áߵ HA, 1,809¸í(13.8%)ÀÌ °æÁõ HA·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌó·³ Ç÷¿ìº´ À¯º´·üÀÇ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È À¯µ¿¼º ÁöÇ÷Á¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¸ÅÃâ ¹× 2028³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¼¼ºÐÈ­

¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº Àç·á, Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

Àç·áº°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº ¼Ò Á©¶óƾ°ú µÅÁö Á©¶óƾÀ¸·Î ¾çºÐµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ ¼Ò Á©¶óƾ ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Á¦Ç°º°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯Ã¼ ÁöÇ÷Á¦ ½ÃÀåÀº º¹ÇÕ ÁöÇ÷Á¦, ¼öµ¿ ÁöÇ÷Á¦, ´Éµ¿ ÁöÇ÷Á¦·Î ±¸ºÐµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯Ã¼ ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ º¹ÇÕ ÁöÇ÷Á¦°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº ÀϹݿܰú, ½ÉÀå¿Ü°ú, Ç÷°ü¿Ü°ú, Á¤Çü¿Ü°ú, ½Å°æ ¹× ôÃ߿ܰú, ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ ÀϹݿܰú ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ·Î ±¸ºÐµÇ¸ç, º´¿ø ¹× Ŭ¸®´Ð ½ÃÀåÀº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, Çѱ¹, È£ÁÖ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ºÐ·ùµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº Áß±¹ÀÌ µ¶Á¡Çß½À´Ï´Ù.

¹Ú½ºÅÍ ÀÎÅͳ»¼Å³Î(Baxter International Inc), ¿¡Æ¼ÄÜ(Johnson & Johnson), È­ÀÌÀÚ(Pfizer Inc), ÅÚ·¹Ç÷º½º(Teleflex Incorporated), 3D ¸ÅÆ®¸¯½º ¸ÞµðÄà Å×Å©³î·¯Áö(3D Matrix Medical Technology), ÀÌÁö½º ¶óÀÌÇÁ»çÀ̾ð½º(Aegis Lifesciences)°¡ ÀÖ´Ù, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ¿äÁ¡

Á¦3Àå Á¶»ç ¹æ¹ý

  • Ä¿¹ö ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - ½ÃÀå »óȲ

    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ PEST ºÐ¼®
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àü¹®°¡ÀÇ °ßÇØ

Á¦5Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ºÎ»óÀ̳ª ¿Ü°ú¼ö¼ú Áõ°¡
    • ³ëÀÎ Àα¸ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼÷·Ã Àü¹®°¡ÀÇ ºÎÁ·°ú ºÒÃæºÐÇÑ »óȯ Á¤Ã¥
  • ½ÃÀå ±âȸ
    • º´¿ø¼ö¿Í ¼ö¼ú ¼¾ÅÍ ¼ö Áõ°¡
  • ÇâÈÄ µ¿Çâ
    • Á¦Ç° Çõ½ÅÀ¸·Î À̾îÁö´Â ¿¬±¸°³¹ß(R&D) Ȱµ¿
  • ¿µÇ⠺м®

Á¦6Àå À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¸ÅÃâ°ú ¿¹Ãø ºÐ¼®
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¸ÅÃâ ¿¹Ãø°ú ºÐ¼®

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ºÐ¼® - ¼ÒÀ纰

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : Àç·áº° Á¡À¯À²(2021³â, 2028³â)
  • ¼Ò Á©¶óƾ
  • µÅÁö Á©¶óƾ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ºÐ¼® - Á¦Ç°º°

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : Á¦Ç°º° Á¡À¯À², 2021³â ¹× 2028³â(%)
  • ÄÞºñ³×ÀÌ¼Ç ÁöÇ÷Á¦
    • ÄÞºñ³×ÀÌ¼Ç ÁöÇ÷Á¦ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø
  • ÆÐ½Ãºê ÁöÇ÷Á¦
    • ÆÐ½Ãºê ÁöÇ÷Á¦ : ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø
  • Ȱ¼ºÇü ÁöÇ÷Á¦
    • Ȱ¼º ÁöÇ÷Á¦ : ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø

Á¦9Àå À¯µ¿¼º ÁöÇ÷Á¦ ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå : ¿ëµµº°

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¿ëµµº° Á¡À¯À²(2021³â, 2028³â)
  • ÀϹݿܰú
    • ÀϹݿܰú ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø
  • ½ÉÀå¿Ü°ú
    • ½ÉÀå¿Ü°ú : ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø
  • Ç÷°ü¿Ü°ú
    • Ç÷°ü¿Ü°ú ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø
  • Á¤Çü¿Ü°ú
    • Á¤Çü¿Ü°ú °³¿ä
    • Á¤Çü¿Ü°ú ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø
  • ½Å°æ¡¤Ã´Ã߿ܰú
    • ½Å°æ¡¤Ã´Ã߿ܰú : ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø
  • ±âŸ
    • ±âŸ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° Á¡À¯À²(2021³â, 2028³â)
  • º´¿ø ¹× Áø·á¼Ò
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø : ±¹°¡º° ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦12Àå À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - ¾÷°è »óȲ

  • À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀÇ ¼ºÀå Àü·«(%)
  • À¯±âÀû Àü°³
  • ¹«±âÀû Àü°³

Á¦13Àå ±â¾÷ °³¿ä

  • Baxter International Inc
  • Ethicon(Johnson & Johnson)
  • Pfizer Inc.
  • Teleflex Incorporated
  • 3-D Matrix Medical Technology
  • Aegis Lifesciences

Á¦14Àå ºÎ·Ï

ksm 24.06.20

The Asia Pacific flowable hemostats market is expected to grow from US$ 176.64 million in 2022 to US$ 275.19 million by 2028. It is estimated record a CAGR of 7.7% from 2022 to 2028.

Increasing Number of Hospitals and Surgical Centers Fuels Asia Pacific Flowable Hemostats Market

Injuries are still a significant concern to public health. An increase in global trauma and accident cases is a major driver of the Asia Pacific flowable hemostats market. According to World Health Organization (WHO), annually approximately 1.3 million people cut short their lives because of a road traffic crash. Between 20 to 50 million people suffer non-fatal injuries, with many incurring a disability because of their injury. Globally, hemorrhage or excessive bleeding is responsible for over one-third of pre-hospital deaths and over 40% of deaths within the first 24 hours. The number of surgeries is rising owing to the increasing musculoskeletal disorders related with sports, occupational injuries, and age-related dysfunction. However, a substantial proportion of health gains are lost owing to sports-related injuries. The National Library of Medicine report states China as a large base of patients agonizing traumatic brain injury (TBI) compared to other countries, making this condition a major public health concern. Thus, increasing number of injuries and surgical procedures are responsible for the high adoption of flowable hemostats, thereby driving the market's growth during the forecast period.

Asia Pacific Flowable Hemostats Market Overview

The Asia Pacific flowable hemostats market is segmented into China, Japan, India, South Korea, Australia, and the rest of Asia Pacific. The Asia Pacific region is expected to be the fastest-growing region among all other regions. The growth of market in the Asia Pacific region is expected to grow at a faster pace owing to investments made in the infrastructure development of the healthcare sector, rising number of surgical procedures, growing emphasis on providing superior surgical outcomes, and favorable regulatory approvals. China holds a considerable share in the Asia Pacific flowable hemostats market. The market is expected to grow owing to the growing emphasis on providing superior surgical care, and the growing demand for modern healthcare instruments. The rise in the prevalence of bleeding disorders has paved the way for the design, development, and piloting of flowable hemostats. According to a Hemophilia Treatment Center Collaboration Network of China (HTCCNC) study, HTCCNC identified 17,779 patients with Hemophilia A from 2007 to 2019. Patients were predominantly male (99.99%), and 28.3% had a known family history of hemophilia. Among patients with lab-measured disease severity (N = 13,116), 6,519 had severe HA (49.7%), 4,788 had moderate HA (36.5%), and 1,809 had mild HA (13.8%). Thus, rising incidences of hemophilia will increase the demand for flowable hemostats during the forecast period.

Asia Pacific Flowable Hemostats Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Flowable Hemostats Market Segmentation

The Asia Pacific flowable hemostats market is segmented into material , product, application, end user, and country .

Based on material, the Asia Pacific flowable hemostats market is bifurcated into bovine gelatin and porcine gelatin. The bovine gelatin segment held a larger share of the Asia Pacific flowable hemostats market in 2022.

In terms of product , the Asia Pacific flowable hemostats market is segmented into combination hemostats , passive hemostats, and active hemostats . The combination hemostats segment held the largest share of the Asia Pacific flowable hemostats market in 2022.

Based on application , the Asia Pacific flowable hemostats market is categorized into general surgery , cardiac surgery, vascular surgery, orthopedic surgery, neuro and spine surgery, and others . The general surgery segment held the largest share of the Asia Pacific flowable hemostats market in 2022.

Based on end user , the Asia Pacific flowable hemostats market is segmented into hospitals and clinics , ambulatory surgery centers, and others . The hospitals and clinics segment held the largest share of the Asia Pacific flowable hemostats market in 2022.

By country, the Asia Pacific flowable hemostats market is categorized int o China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific flowable hemostats market in 2022.

Baxter International Inc, Ethicon (Johnson & Johnson), Pfizer Inc, Teleflex Incorporated, 3-D Matrix Medical Technology, and Aegis Lifesciences are some of the leading companies operating in the Asia Pacific flowable hemostats market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Asia Pacific Flowable Hemostats Market - By Material
    • 1.3.2 Asia Pacific Flowable Hemostats Market - By Product
    • 1.3.3 Asia Pacific Flowable Hemostats Market - By Application
    • 1.3.4 Asia Pacific Flowable Hemostats Market - By End User
    • 1.3.5 Asia Pacific Flowable Hemostats Market - By Country

2. Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Flowable Hemostats Market - Market Landscape

  • 4.1 Overview
    • 4.1.1 Asia Pacific PEST Analysis
  • 4.2 Asia Pacific Experts Opinion

5. Asia Pacific Flowable Hemostats Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increasing Number of Injuries and Surgical Procedures
    • 5.1.2 Rising Geriatric Population
  • 5.2 Market Restraints
    • 5.2.1 Shortage of Skilled Professionals and Poor Reimbursement Policies
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Number of Hospitals and Surgical Centers
  • 5.4 Future Trends
    • 5.4.1 Research and Development (R&D) Activities Leading to Product Innovations
  • 5.5 Impact Analysis

6. Flowable Hemostats Market - Asia Pacific Analysis

  • 6.1 Asia Pacific Flowable Hemostats Market Revenue Forecast & Analysis
    • 6.1.1 Asia Pacific Flowable Hemostats Market Revenue Forecast & Analysis

7. Asia Pacific Flowable Hemostats Market Analysis - By Material

  • 7.1 Asia Pacific Flowable Hemostats Market Share, by Material, 2021 and 2028 (%)
  • 7.2 Bovine Gelatin
    • 7.2.1 Overview
    • 7.2.2 Bovine Gelatin: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 7.3 Porcine Gelatin
    • 7.3.1 Overview
    • 7.3.2 Porcine Gelatin: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)

8. Asia Pacific Flowable Hemostats Market- By Product

  • 8.1 Overview
  • 8.2 Asia Pacific Flowable Hemostats Market Share, by Product, 2021 and 2028 (%)
  • 8.3 Combination Hemostat
    • 8.3.1 Overview
    • 8.3.2 Combination Hemostat: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Passive Hemostat
    • 8.4.1 Overview
    • 8.4.2 Passive Hemostat: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Active Hemostat
    • 8.5.1 Overview
    • 8.5.2 Active Hemostat: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Flowable Hemostats Market- By Application

  • 9.1 Overview
  • 9.2 Asia Pacific Flowable Hemostats Market Share, by Application, 2021 and 2028 (%)
  • 9.3 General Surgery
    • 9.3.1 Overview
    • 9.3.2 General Surgery: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Cardiac Surgery
    • 9.4.1 Overview
    • 9.4.2 Cardiac Surgery: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Vascular Surgery
    • 9.5.1 Overview
    • 9.5.2 Vascular Surgery: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.6 Orthopedic Surgery
    • 9.6.1 Overview
    • 9.6.2 Orthopedic Surgery: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.7 Neuro and Spine Surgery
    • 9.7.1 Overview
    • 9.7.2 Neuro and Spine Surgery: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.8 Others
    • 9.8.1 Overview
    • 9.8.2 Others: Asia Pacific Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Flowable Hemostats Market Analysis - By End User

  • 10.1 Overview
  • 10.2 Asia Pacific Flowable Hemostats Market Share, by End User, 2021 and 2028, (%)
  • 10.3 Hospitals and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospitals and Clinics: Asia Pacific Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Ambulatory Surgery Centers
    • 10.4.1 Overview
    • 10.4.2 Ambulatory Surgery Centers: Asia Pacific Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Others
    • 10.5.1 Overview
    • 10.5.2 Others: Asia Pacific Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)

11. Asia Pacific Flowable Hemostats Market Revenue and Forecasts to 2028 - Country Analysis

  • 11.1 Asia Pacific: Flowable Hemostats Market
    • 11.1.1 Overview
    • 11.1.2 Asia Pacific: Flowable Hemostats Market, by Country, 2021 & 2028 (%)
      • 11.1.2.1 China: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.1.1 China: Flowable Hemostats Market Revenue and Forecast to 2028 (US$ Mn)
        • 11.1.2.1.2 China: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.1.3 China: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.1.4 China: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.1.5 China: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)
      • 11.1.2.2 Japan: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.2.1 Japan: Flowable Hemostats Market Revenue and Forecast to 2028 (US$ Mn)
        • 11.1.2.2.2 Japan: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.2.3 Japan: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.2.4 Japan: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.2.5 Japan: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)
      • 11.1.2.3 India: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.3.1 India: Flowable Hemostats Market Revenue and Forecast to 2028 (US$ Mn)
        • 11.1.2.3.2 India: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.3.3 India: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.3.4 India: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.3.5 India: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)
      • 11.1.2.4 South Korea: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.1 South Korea: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.2 South Korea: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.3 South Korea: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.4 South Korea: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.5 South Korea: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)
      • 11.1.2.5 Australia: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.5.1 Australia: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.5.2 Australia: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.5.3 Australia: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.5.4 Australia: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.5.5 Australia: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)
      • 11.1.2.6 Rest of Asia Pacific: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.6.1 Rest of Asia Pacific: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.6.2 Rest of Asia Pacific: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.6.3 Rest of Asia Pacific: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.6.4 Rest of Asia Pacific: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.6.5 Rest of Asia Pacific: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)

12. Flowable Hemostats Market-Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in the Flowable Hemostats Market (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Baxter International Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Ethicon (Johnson & Johnson)
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Pfizer Inc.
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Teleflex Incorporated
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 3-D Matrix Medical Technology
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Aegis Lifesciences
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments

14. Appendix

  • 14.1 About the Insight Partners
  • 14.2 Asia Pacific Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦